Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

Xconomy: Tobira Fails Main Goal in NASH Study, But Forges Ahead To Next Trial

2018-02-11 xconomy
[Updated, 9:40 a.m. ET, see below] Developing treatments for nonalcoholic steatohepatitis, a dangerous liver disease that’s fast becoming an epidemic, is one of the most competitive fields in biotech. Tobira Therapeutics is one of several companies in the mix, and although data released this morning cast doubt on the potential of its drug, the company plans to forge ahead nonetheless. (45-0)

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List

2018-02-06 seekingalpha
Readers are encouraged to make their voices heard in my recent blog post if they haven´t already. (647-3)

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

2018-02-02 seekingalpha
I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY. (539-1)

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

2018-01-30 seekingalpha
So far feedback has been positive for new features added, namely the position explanation section and updated model account snapshot. (330-0)

2 Small Biotechs With Substantial Upside Potential

2018-01-26 seekingalpha
The biotech sector is perking up this week on the back of two big acquisitions and improved sentiment on the space. (26-1)

ROTY Edition 1 Volume 73: New Features And A Controversial Swap Out

2018-01-25 seekingalpha
We are swapping out a current holding for a recent addition to the Contenders List (please read full write-up and be aware of risks). (158-4)

Can-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs

2018-01-08 accesswire
SANTA MONICA, CA / ACCESSWIRE / January 8, 2018 / Non-alcoholic steatohepatitis, or NASH as it is more frequently called, is an advanced form of non-alcoholic fatty liver disease (NAFLD) characterized by buildup of fat in the liver and related inflammation and damage not caused by alcohol use. In some biotech circles, NASH is understandably called the next great untapped market due to the fact that there is a dearth of treatments for the disease that affects up to 30 million Americans. (4-0)

Conatus: Likely To Dash Ahead Of NASH Data

2017-12-13 seekingalpha
Conatus, with emricasan, seeks to halt the progression of liver disease in four separate phase 2 trials. (235-5)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-13)

Tobira Therapeutics 10-K (Annual Report)

2017-10-05 sec.gov
10-K Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-K       x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR   ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35953     REGADO BIOSCIENCES, INC.

Tobira Therapeutics PREM14A

2017-10-04 sec.gov
PREM14A Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934     Filed by the Registrant  x                             Filed by a Party other than the Registrant   ¨ Check the appropriate box:   x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional

Tobira Therapeutics DEFM14A

2017-10-04 sec.gov
DEFM14A Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934     Filed by the Registrant  x                             Filed by a Party other than the Registrant   ¨ Check the appropriate box:   ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional

CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions

2017-09-26 prnewswire
SEATTLE, Sept. 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed its new Chairman of the Board and the promotion of David H. Kirske to Chief Financial Officer and Bruce J. Seeley to Chief Operating Officer of the company. (98-0)


CUSIP: 88883P101